Developing a new viral therapy for treating glioblastoma brain tumors
Next generation oncolytic virotherapy targeting AKT and ERK signaling in glioma
['FUNDING_R01'] · AUGUSTA UNIVERSITY · NIH-11087617
This study is testing a new virus treatment for glioblastoma, a tough brain tumor, to see if it can help kill tumor cells and boost the immune system while working alongside current treatments, with the hope of reducing seizures and improving life for patients.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | AUGUSTA UNIVERSITY (nih funded) |
| Locations | 1 site (AUGUSTA, UNITED STATES) |
| Trial ID | NIH-11087617 on ClinicalTrials.gov |
What this research studies
This research focuses on creating a novel oncolytic viral therapy specifically designed to target glioblastoma, a highly aggressive brain tumor. The approach involves using a virus that can destroy tumor cells while also stimulating the body's immune response against the cancer. Researchers will evaluate the effectiveness of this therapy in combination with existing treatments like radiation and Temozolomide, and assess its potential to reduce seizure frequency in patients. By studying the interactions between the virus and the tumor environment, the goal is to enhance treatment outcomes and improve the quality of life for patients suffering from glioblastoma.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults diagnosed with glioblastoma who may benefit from innovative treatment approaches.
Not a fit: Patients with other types of brain tumors or those who are not diagnosed with glioblastoma may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for glioblastoma patients, potentially extending survival and improving quality of life.
How similar studies have performed: Previous research has shown promising results with oncolytic viral therapies in treating various cancers, indicating potential for success in this novel approach.
Where this research is happening
AUGUSTA, UNITED STATES
- AUGUSTA UNIVERSITY — AUGUSTA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: KAUR, BALVEEN — AUGUSTA UNIVERSITY
- Study coordinator: KAUR, BALVEEN
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.